GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
https://www.theguardian.com/business/live/2026/jun/09/chip-stocks-bounce-back-kospi-openai-wall-street-float-stock-markets-oil-live-news-updates">Business live – latest updates
https://www.theguardian.com/business/2025/sep/29/gsk-emma-walmsley-to-be-replaced-as-ceo">GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels">Continue reading...GSK Acquires Nuvalent for $10.6 Billion
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —